Father–son drug-discovery bet on reversing renal fibrosis — incubator-validated premise, almost no public pipeline.
NephroNovus
venture active confidence: Low status: Draft updated 2026-07-14
Summary
NephroNovus is a kidney-fibrosis therapeutics venture listed only as an Altitude Lab alumnus. Reversing renal fibrosis would matter enormously, but the page has no verified program, candidate, financing, or results; an unsupported aspiration earns no impact credit.
Impact
Chronic kidney disease affects hundreds of millions of people worldwide. Established therapies mostly slow decline; no widely approved drug reverses established renal fibrosis at scale. Fibrosis also connects CKD progression to dialysis and transplant burden.
If NephroNovus could safely reverse or materially regress renal fibrosis in humans, the clinical and economic impact would be large. At this evidence level, that remains a scientific premise, not a demonstrated company capability. CKD drug discovery is crowded and failure-prone; many antifibrotic approaches have stalled in clinic.
What They Are Building
Public materials support only a high-level model:
- Problem: Chronic kidney disease progression driven in part by renal fibrosis (scarring).
- Approach: Combine biochemical pathway discovery with computational innovation (exact targets and algorithms undisclosed).
- Stage: Early drug-discovery company; no published results or trial registrations tied to NephroNovus were found in sources captured here.
Do not infer a specific modality (small molecule, biologic, RNA, etc.) from portfolio language alone.
What They Need Now
Likely needs for a company at this stage include renal fibrosis biology expertise, medicinal chemistry or biologics discovery, computational drug-discovery engineering, preclinical pharmacology, IP counsel, and seed fundraising. A two-founder team (if still accurate) implies high leverage per contributor but also key-person risk.
Who Could Help
Useful helpers — if the company is actively building — include CKD clinical KOLs, renal fibrosis model CRO partners, computational chemistry advisors, and early biotech investors comfortable with binary preclinical risk. Altitude Labs alumni network may remain a connector even after residency ends.
Utah Context
NephroNovus is part of the Altitude Lab portfolio on Salt Lake City's Recursion-adjacent life-science campus — the same ecosystem as Evolution Bio, Sethera Therapeutics, and CaLycia Biosciences. The father–son origin story ties the venture to Utah nephrology research culture, though the specific academic lab affiliation is not documented on the portfolio page itself.
Evidence
See Also
- Altitude Labs — Utah health-care incubator that listed NephroNovus
- Evolution Bio — another early Altitude Lab–associated Utah platform/discovery company with sparse public disclosure
Open Questions
- Careers URL: No public careers board found (2026-07-14). Extremely early / alumni incubator status;
nephronovus.comis branding-only. Do not invent Careers. - Pipeline and mechanism — no public disclosure of targets, hits, or lead series.
- Funding — no announced round, grant, or SBIR award verified in sources reviewed.
- Residency vs. alumni status — portfolio lists Alumni; confirm whether the company still uses Altitude Lab space or services.
- Team size and hiring — what are the current headcount and hiring plans?